Used in pharmaceutical research as a key intermediate in the synthesis of targeted protein degraders, particularly cereblon E3 ligase modulators. Its structure enables selective binding to cereblon, making it valuable in developing PROTACs (proteolysis-targeting chimeras) for cancer therapy and immune modulation. The compound's piperazine and piperidine dione moieties enhance solubility and binding affinity, supporting optimization of drug candidates with improved pharmacokinetic profiles.